Turning Point Therapeutics Inc. (TPTX) Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive TKI-Naïve Non-Small Cell Lung Cancer
Go back to Turning Point Therapeutics Inc. (TPTX) Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive TKI-Naïve Non-Small Cell Lung Cancer| TORREYPINES THERA (NASDAQ: TPTX) | Delayed: 76.01 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $76.01 | 52 Week High | $0.69 | |||
| Open | $76.01 | 52 Week Low | $0.07 | |||
| Day High | $76.01 | P/E | N/A | |||
| Day Low | $76.01 | EPS | $-0.90 | |||
| Volume | 101 | |||||
